CODA Biotherapeutics acquires Attenua and three clinical stage assets

BY      |     February 7, 2020

CODA Biotherapeutics, a biopharmaceutical company developing a gene therapy approach for the treatment of neurological diseases, announced the acquisition of Attenua with its three clinical stage small molecule drugs. CODA has engineered a set of ligand-gated ion channels that can be specifically controlled by these drugs.

CODA plans to advance these unique channel-ligand pairs toward the clinic to treat neuropathic pain, focal epilepsy, and other neurologic diseases and disorders.

Read more about CODA Biotherapeutics here.

Image by Gerd Altmann from Pixabay

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.